Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer

Sacituzumab Govitecan (SG) is an antibody-drug conjugate (ADC) comprised of an anti-Trop-2 IgG1 molecule conjugated to SN-38, the active metabolite of irinotecan, via a pH-sensitive hydrolysable linker. As a result of recent Canadian funding for SG in advanced hormone receptor (HR)-positive breast cancer and triple-negative breast cancer (TNBC), experience with using SG and managing adverse events (AEs) has grown. This review presents a summary of evidence and adverse event recommendations derived from Canadian experience, with SG use in metastatic TNBC for extrapolation and guidance in all indicated settings. SG is dosed at 10 mg/kg on day 1 and day 8 of a 21-day cycle. Compared to treatment of physicians’ choice (TPC) the phase III ASCENT and TROPiCS-02 studies demonstrated favorable survival data in unresectable locally advanced or metastatic TNBC and HR-positive HER2 negative metastatic breast cancer, respectively. The most common AEs were neutropenia, diarrhea, nausea, fatigue, alopecia, and anemia. This review outlines AE management recommendations for SG based on clinical trial protocols and Canadian guidelines, incorporating treatment delay, dose reductions, and the use of prophylactic and supportive medications.

• Publication year

  2024

• Venue

  Current Oncology

• Publication date

  2024-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/curroncol31090422PMID 39330050PMCID 11431578
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.

  2024influential reference
• Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

  2024cited by this paper
• Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial.

  2023cited by this paper
• Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.

  2023influential reference
• Optimizing the safety of antibody–drug conjugates for patients with solid tumours

  2023cited by this paper
• Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

  2023cited by this paper
• ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.

  2023cited by this paper
• 2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents

  2023cited by this paper
• Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

  2022influential reference
• 276TiP ASCENT-04/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician’s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)

  2022cited by this paper
• 275TiP ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)

  2022cited by this paper
• Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

  2022influential reference
• Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.

  2022cited by this paper
• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

  2022cited by this paper
• 168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study

  2022cited by this paper
• Sacituzumab Govitecan (Trodelvy)

  2022cited by this paper
• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

  2021influential reference
• TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

  2021cited by this paper
• Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  2021cited by this paper
• Sacituzumab Govitecan, a Trop-2-Directed Antibody-Drug Conjugate, for Patients with Epithelial Cancer: Final Safety and Efficacy Results from the Phase 1/2 IMMU-132-01 Basket Trial.

  2021influential reference
• Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy

  2020cited by this paper
• HER2-Low Breast Cancer: Pathological and Clinical Landscape.

  2020cited by this paper
• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

  2020cited by this paper
• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

  2019cited by this paper
• Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

  2019cited by this paper
• Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer

  2019cited by this paper
• Antibody-drug conjugates for cancer.

  2019influential reference
• Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

  2019cited by this paper
• Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

  2018cited by this paper
• Significance of UGT1A1*28 Genotype in Patients with Advanced Liver Injury Caused By Chronic Hepatitis C

  2018cited by this paper
• Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

  2017influential reference
• Biology and Management of Patients With Triple-Negative Breast Cancer.

  2016cited by this paper
• Features of triple-negative breast cancer

  2016cited by this paper
• Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State

  2015cited by this paper
• The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer

  2015cited by this paper
• An FDA oncology analysis of antibody-drug conjugates.

  2015cited by this paper
• First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

  2015cited by this paper
• PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION

  2015influential reference
• Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

  2015influential reference
• PharmGKB summary: very important pharmacogene information for UGT1A1

  2014cited by this paper
• Trop-2 Is a Determinant of Breast Cancer Survival

  2014cited by this paper
• Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia

  2014cited by this paper
• Upregulation of Trop-2 quantitatively stimulates human cancer growth

  2013cited by this paper
• Triple-negative breast cancer: epidemiological considerations and recommendations.

  2012cited by this paper
• Trastuzumab emtansine for HER2-positive advanced breast cancer.

  2012cited by this paper
• Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

  2012cited by this paper
• Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk

  2010cited by this paper
• HIGHLIGHTS OF PRESCRIBING INFORMATION

  2009cited by this paper
• UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

  2007cited by this paper
• Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

  2004cited by this paper
• Human TROP‐2 is a tumor‐associated calcium signal transducer

  1998cited by this paper

• Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy

  2025cites this paper
• Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan

  2025cites this paper
• Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis

  2025cites this paper
• Risk-Stratified Management of ADC drug-Related Neutropenia: Integrating Clinical Trial Meta-Summary and Existing Guideline Principles.

  2025cites this paper
• Taiwan Expert Consensus on the Clinical Integration of Antibody-Drug Conjugates in Advanced Breast Cancer

  2025cites this paper
• The efficacy and safety of sacituzumab govitecan in the treatment of breast cancer: a systemic review and meta-analysis of emerging clinical data

  2025cites this paper
• Adverse events induced by the subcutaneous HER2-targeted antibody-drug conjugate JSKN033 in a male patient with breast cancer: A case report

  2025cites this paper